Intrathecal MoRphine versus TAP Block for AnalGesic management in Elective caesarean section performed under neuraxial anesthesia. A monocentric pilot randomized controlled trial. The MIRAGE trial.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513150-29-00

Acronym

The MIRAGE trial

Enrollment

100

Registered

2024-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cesarean section

Brief summary

The primary endpoint of this trial is the determination of how many times somatic VAS at rest is 6 or more in the different evaluations at 12 AM, 6 PM, 00 AM (or at 6 PM, 00 AM and 6 AM if the CS is performed after 12 AM) and at 24 hours from the spinal anesthesia

Interventions

DRUGROPIVACAINA CLORIDRATO BIOINDUSTRIA L.I.M. 10 mg/ml soluzione iniettabile

DRUGMorfina cloridrato S.A.L.F. 10 mg/ml soluzione iniettabile

DRUGCATAPRESAN 150 microgrammi/ml soluzione iniettabile

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoint of this trial is the determination of how many times somatic VAS at rest is 6 or more in the different evaluations at 12 AM, 6 PM, 00 AM (or at 6 PM, 00 AM and 6 AM if the CS is performed after 12 AM) and at 24 hours from the spinal anesthesia	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026